References
- Davidson MB. Starting insulin therapy in type 2 diabetic patients: does it really matter how? Diabetes Care 2005;28: 494–5
- Mikhail NE, Cope D. Initiation of insulin in patients with type 2 diabetes failing oral therapy: response to Raskin et al. and Janka et al. Diabetes Care 2005;28:1537–8
- Raskin P. Initiation of insulin therapy in patients with type 2 diabetes failing oral therapy: response to Mikhail and Cope and to Janka. Diabetes Care 2005;28:2811
- Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28:260–65
- National Institute for Clinical Excellence. Technology Appraisal Guidance – No. 53. Guidance on the use of long-acting insulin analogues for the treatment of diabetes – insulin glargine. London: NICE, 2002
- Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):5–26
- Lee AJ, Morgan CL, Morrissey M et al. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with type 1 diabetes, type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005;22:1482–6
- Valentine WJ, Palmer AJ, Lammert M, et al. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 vs insulin glargine in insulin naïve type 2 diabetes patients: cost effectiveness analysis in a UK setting. Curr Med Res Opin 2005;21:2063–71
- The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53